Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. IXJ iShares Global Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 15 Sep 2014

    This fund holds major U.S. health-care companies and mega-cap foreign firms such as Novartis NVS, Roche, and Sanofi SNY , with foreign firms making up about 37% of the fund's assets. We would caution investors, however, that the dynamics

  2. MannKind: Nothing But Good News, Trading Volume Drops, Short Interest Remains Sky High

    Headlines

    Thu, 11 Sep 2014

    Analyst : More Details about the Sanofi /MannKind Deal Emerge from the Morgan ..... 65/35 profit sharing deal with Sanofi will yield them the equivalent of ..... terms of the agreement mean that Sanofi (NYSE: SNY ) will be fronting MNKD's development

  3. Lilly, Boehringer copy of Sanofi's insulin gets EU approval

    Headlines

    Wed, 10 Sep 2014

    Sept 10 (Reuters) - Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA 's blockbuster insulin, Lantus.

  4. Sanofi : Riding The Growth Trend

    Headlines

    Mon, 8 Sep 2014

    By Balanced Investing : Sanofi (NYSE: SNY ) is a healthcare company engaged ..... In my article, I will analyze Sanofi 's pipeline and its valuation. Positive Data from Sanofi and Regeneron Pharmaceutical's

  5. There Is Further Upside Potential In Regeneron Pharmaceuticals

    Headlines

    Mon, 8 Sep 2014

    announced positive results from four Phase III trials for its potential blockbuster drug, alirocumab. Regeneron and Sanofi (NYSE: SNY ) have also purchased a priority review voucher for alirocumab U.S. FDA submission, which has given them a chance

  6. Challenging Consensus On PCSK9 Inhibitors: Focus On Regeneron And Amgen

    Headlines

    Mon, 8 Sep 2014

    include AMGN and REGN, REGN's joint venture partner Sanofi (NYSE: SNY ), Pfizer (NYSE: PFE ) and Eli Lilly (NYSE: LLY ..... and European marketing approval late last month; REGN/ SNY intend to file by year-end. Pfizer and Lilly lag

  7. Lilly basal insulin beats Lantus

    Headlines

    Fri, 5 Sep 2014

    basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared to Sanofi 's (NYSE: SNY ) Lantus ( insulin glargine ) at 26 and 52 weeks in patients with Type 1 diabetes. Both trials showed the rate

  8. New Morningstar Analyst Report for Sanofi

    Stock Reports

    Fri, 5 Sep 2014

    Sanofi 's strong ..... should mean Sanofi will have ..... insulin market, Sanofi 's Lantus ..... lifestyles. Sanofi 's increasingly ..... exemplary. Since Chris Viehbacher took over ..... understanding of Sanofi 's home country ..... May 2010, Serge Weinberg took over

  9. 2 Compelling Reasons To Buy Pfizer

    Headlines

    Thu, 4 Sep 2014

    vaccine in the world, Prevnar 13, the company's vaccine division has been trailing those of Merck (NYSE: MRK ), Sanofi (NYSE: SNY ) and GlaxoSmithKline (NYSE: GSK ). Some recent developments though have allowed Pfizer to close the gap. Last

  10. Lilly's diabetes drug trumps Sanofi's in late-stage trials

    Headlines

    Thu, 4 Sep 2014

    Sept 4 (Reuters) - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA 's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.

« Prev12345Next »
Content Partners